LXRX - Lexicon Pharmaceuticals Inc.

LXRX Stock Chart

LXRX Profile

Lexicon Pharmaceuticals, Inc., a prominent biopharmaceutical firm, specializes in the rigorous exploration, advancement, and commercialization of innovative pharmaceutical products. The company's research and development efforts are primarily focused on orally-administered small molecule drug candidates that hold promise across various therapeutic areas.

Among its notable developments is Sotagliflozin, a leading candidate that has successfully completed Phase III clinical trials. This drug is being evaluated for its potential applications in treating heart failure and type 1 diabetes, aiming to address significant unmet medical needs in these critical health conditions.

In addition to Sotagliflozin, Lexicon Pharmaceuticals is advancing LX9211 through Phase II clinical development. LX9211 targets neuropathic pain, underscoring the company's commitment to addressing chronic pain management with novel therapeutic solutions.

Lexicon Pharmaceuticals operates through strategic collaboration and licensing agreements with industry giants such as Bristol-Myers Squibb Company and Genentech, Inc., leveraging these partnerships to bolster its research capabilities and broaden its reach in the competitive biopharmaceutical landscape. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals continues to drive innovation in drug discovery and development, aiming to improve patient outcomes worldwide.

LXRX Revenue Chart

LXRX Earnings

Analyst Ratings